UBS: Upgrade LI NING (02331) rating to "buy" target price of 28.6 Hong Kong dollars. Expected acceleration in first quarter sales growth.
Expected first quarter sales growth this year will significantly accelerate by quarter, turning from a low single-digit decline to a high single-digit increase, mainly driven by the strong performance of the Glory series, new outdoor categories, as well as badminton and running shoe products.
UBS released a research report stating that it has raised its investment rating for LI NING (02331) from "neutral" to "buy". The bank expects significant acceleration in sales growth in the first quarter of this year, with low single-digit declines turning into high single-digit increases. This growth is mainly driven by the Glory series, new outdoor categories, and strong performance in badminton and running shoe products. UBS has raised its net profit forecasts for 2025 to 2027 by 4% to 7%, and the target price has been raised from HK$21.8 to HK$28.6, equivalent to a forecast price-to-earnings ratio of 18 for 2027. UBS predicts LI NING's earnings per share for 2026 to 2029 to be RMB 1.18, 1.37, 1.55, and 1.7 respectively.
Related Articles

Fuan Pharmaceutical (300194.SZ) subsidiary has received approval for a chemical raw material drug to be listed.

Apple Inc. (AAPL.US) is in intensive discussions with three major banks in India, planning to launch Apple Pay in the market with a population of 1.4 billion.

Bank of America Merrill Lynch: Reiterated KUAISHOU-W (01024) "Buy" rating with a target price of HK$94.
Fuan Pharmaceutical (300194.SZ) subsidiary has received approval for a chemical raw material drug to be listed.

Apple Inc. (AAPL.US) is in intensive discussions with three major banks in India, planning to launch Apple Pay in the market with a population of 1.4 billion.

Bank of America Merrill Lynch: Reiterated KUAISHOU-W (01024) "Buy" rating with a target price of HK$94.

RECOMMEND

Robot Concept Hong Kong Stocks Retreat After Spring Gala Rally As 2026 Emerges As Pivotal Year For Mass Production And Commercialization
25/02/2026

Hong Kong IPO Fundraising Surges Tenfold At Start Of Year As 110 A‑Share Companies Queue For Listings
25/02/2026

AI Iteration Risks Surface As Hong Kong Market Diverges; Low‑Valuation, High‑Dividend Legacy Stocks Attract Capital As Safe Havens
25/02/2026


